{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:08:53Z","timestamp":1783350533226,"version":"3.54.6"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005347","name":"American Association for the Study of Liver Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.aohep.2025.101905","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T08:00:57Z","timestamp":1742630457000},"page":"101905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Latin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Mar\u00eca Margarita","family":"Anders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Z.","family":"Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 D.","family":"Debes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Coste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Lopes","family":"Chagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josemar\u00eda","family":"Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Carrera","family":"Estupi\u00f1an","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5005","authenticated-orcid":false,"given":"Javier Diaz","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo A.","family":"Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pi\u00f1ero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2025.101905_bib0001","unstructured":"Fact sheets by population-globocan IARC 2022."},{"issue":"S4","key":"10.1016\/j.aohep.2025.101905_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The Incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"The Oncologist"},{"issue":"6","key":"10.1016\/j.aohep.2025.101905_bib0003","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101905_bib0004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101905_bib0005","article-title":"AFP score and metroticket 2.0 perform similarly and could be used in a \"within-ALL\" clinical decision tool","volume":"5","author":"Pinero","year":"2023","journal-title":"JHEP Rep"},{"issue":"7","key":"10.1016\/j.aohep.2025.101905_bib0006","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101905_bib0007","first-page":"e0157","article-title":"Updates in liver transplantation policy for patients with hepatocellular carcinoma (HCC)","volume":"23","author":"Mehta","year":"2024","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"4","key":"10.1016\/j.aohep.2025.101905_bib0008","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1394143","article-title":"Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST","volume":"34","author":"Reig","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"5","key":"10.1016\/j.aohep.2025.101905_bib0009","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.aohep.2025.101905_bib0010","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101905_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101905_bib0012","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J Gastroenterol"},{"issue":"10064","key":"10.1016\/j.aohep.2025.101905_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.aohep.2025.101905_bib0014","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.aohep.2025.101905_bib0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.aohep.2025.101905_bib0016","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101905_bib0017","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101905_bib0018","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101905_bib0019","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.aohep.2025.101905_bib0020","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"10408","key":"10.1016\/j.aohep.2025.101905_bib0021","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.aohep.2025.101905_bib0022","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.aohep.2025.101905_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW. 42","volume":"42","author":"Galle","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10415","key":"10.1016\/j.aohep.2025.101905_bib0024","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/S0140-6736(23)01962-1","article-title":"IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma","volume":"402","author":"Vogel","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2025.101905_bib0025","series-title":"EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization","author":"Lencioni","year":"2024"},{"issue":"4","key":"10.1016\/j.aohep.2025.101905_bib0026","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00270-021-03031-9","article-title":"Randomized phase 3 LEAP-012 study: transarterial chemoembolization with or without Lenvatinib plus Pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment","volume":"45","author":"Llovet","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101905_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101112","article-title":"The leading and key role of hepatologists in the multidisciplinary management of patients with hepatocellular carcinoma","volume":"28","author":"Marin","year":"2023","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101905_bib0028","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.aohep.2025.101905_bib0029","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.aohep.2025.101905_bib0030","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.aohep.2025.101905_bib0031","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only Pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.aohep.2025.101905_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.aohep.2025.101905_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.816198","article-title":"Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: a prospective, multi-center, real-world study","volume":"12","author":"You","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.aohep.2025.101905_bib0034","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101905_bib0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"10.1016\/j.aohep.2025.101905_bib0036","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101905_bib0037","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.aohep.2025.101905_bib0038","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MEG.0000000000001049","article-title":"Adherence to Barcelona clinic liver cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina","volume":"30","author":"Pinero","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101905_bib0039","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000531225","article-title":"Adjuvant atezolizumab-bevacizumab after resection or ablation for hepatocellular carcinoma","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"issue":"3","key":"10.1016\/j.aohep.2025.101905_bib0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101905_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.892250","article-title":"Multi-scale spatial analysis of the tumor microenvironment reveals features of Cabozantinib and Nivolumab efficacy in hepatocellular carcinoma","volume":"13","author":"Mi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.aohep.2025.101905_bib0042","unstructured":"Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. (2468-1253 (Electronic\u00e7)."},{"issue":"11","key":"10.1016\/j.aohep.2025.101905_bib0043","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis","volume":"25","author":"D'Alessio","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2025.101905_bib0044","first-page":"696A","article-title":"KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation","volume":"72","author":"Vogel","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.aohep.2025.101905_bib0045","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/j.jvir.2018.12.607","article-title":"Abstract No. 526 CheckMate-9DX: phase 3, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation","volume":"30","author":"Exposito","year":"2019","journal-title":"J Vasc Interv Radiol"},{"issue":"Supplement_4","key":"10.1016\/j.aohep.2025.101905_bib0046","article-title":"A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2","volume":"30","author":"Knox","year":"2019","journal-title":"Ann Oncol"},{"issue":"10415","key":"10.1016\/j.aohep.2025.101905_bib0047","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.aohep.2025.101905_bib0048","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1001\/jamaoncol.2022.4733","article-title":"Association of high levels of antidrug antibodies against Atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma","volume":"8","author":"Kim","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101905_bib0049","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","article-title":"Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease","volume":"79","author":"Meyer","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101905_bib0050","first-page":"202","article-title":"Updated efficacy and safety data from IMbrave050: phase 3 study of adjuvant atezolizumab + bevacizumab vs active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma. 35 (2)","author":"Yopp","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aohep.2025.101905_bib0051","unstructured":"Rodr\u00edguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological mechanisms responsible for radiation-induced abscopal effect. (1471-4981 (Electronic)."},{"issue":"5","key":"10.1016\/j.aohep.2025.101905_bib0052","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2025.101905_bib0053","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.aohep.2025.101905_bib0054","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101905_bib0055","unstructured":"Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. (2468-1253 (Electronic)."},{"key":"10.1016\/j.aohep.2025.101905_bib0056","unstructured":"Llovet JM, Decaens T Fau, Raoul J-L, Raoul Jl, Fau Boucher E, Boucher E Fau-Kudo M, Kudo M Fau-Chang C, Chang C Fau, Kang Y-K, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. (1527-7755 (Electronic)."},{"issue":"1","key":"10.1016\/j.aohep.2025.101905_bib0057","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000531377","article-title":"A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with Lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.aohep.2025.101905_bib0058","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101905_bib0059","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2009.12.032","article-title":"The place of downstaging for hepatocellular carcinoma","volume":"52","author":"Toso","year":"2010","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101905_bib0060","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) Consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.aohep.2025.101905_bib0061","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","article-title":"Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US Multicenter HCC Transplant Consortium","volume":"271","author":"DiNorcia","year":"2020","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.aohep.2025.101905_bib0062","article-title":"International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria","volume":"3","author":"Degroote","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.aohep.2025.101905_bib0063","article-title":"Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation","author":"Li","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101905_bib0064","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/JHC.S342266","article-title":"Recurrent hepatocellular carcinoma: patterns, detection, staging and treatment","volume":"9","author":"Papaconstantinou","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"issue":"4","key":"10.1016\/j.aohep.2025.101905_bib0065","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/hep.32613","article-title":"Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF\/TKI and immunotherapy","volume":"76","author":"Tran","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.aohep.2025.101905_bib0066","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.transproceed.2024.05.041","article-title":"Downstaging of hepatocellular carcinoma before liver transplantation: current advances in selection criteria and therapeutic options","volume":"56","author":"Pang","year":"2024","journal-title":"Transplant Proc"},{"key":"10.1016\/j.aohep.2025.101905_bib0067","doi-asserted-by":"crossref","unstructured":"Maspero M, Bhoori S, Fedele V, Simonotti N, Bella V, Bongini M, et al. Atezolizumab \/bevacizumab as downstaging in hepatocellular carcinoma: an intention-to-tranplant analysis. 80. J Hepatol; 2024:S438.","DOI":"10.1016\/S0168-8278(24)01380-1"},{"key":"10.1016\/j.aohep.2025.101905_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101386","article-title":"Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period","volume":"66","author":"Chen","year":"2021","journal-title":"Transpl Immunol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101905_bib0069","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.aohep.2025.101905_bib0070","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","author":"Rezaee-Zavareh","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101905_bib0071","doi-asserted-by":"crossref","first-page":"11648","DOI":"10.3389\/ti.2023.11648","article-title":"European society of organ transplantation (ESOT) consensus report on downstaging, bridging and immunotherapy in liver Transplantation for hepatocellular carcinoma","volume":"36","author":"Claasen","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.aohep.2025.101905_bib0072","unstructured":"Tabrizian P, Holzner ML, Ajmera V, Kim AK, Zhou K, Schnickel GT, et al. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study. LID - S0168-8278(24)02541-8 [pii] LID 10.1016\/j.jhep.2024.09.003. (1600-0641 (Electronic))."},{"issue":"1","key":"10.1016\/j.aohep.2025.101905_bib0073","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/liv.15419","article-title":"Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis","volume":"43","author":"Kayali","year":"2023","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.aohep.2025.101905_bib0074","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1053\/j.gastro.2017.02.040","article-title":"Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality","volume":"152","author":"Serper","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.aohep.2025.101905_bib0075","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1245\/s10434-013-3413-8","article-title":"Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome","volume":"21","author":"Yopp","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101905_bib0076","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000143","article-title":"Multidisciplinary care for patients with HCC: a systematic review and meta-analysis","volume":"7","author":"Seif El Dahan","year":"2023","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.aohep.2025.101905_bib0077","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210730","article-title":"Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients","volume":"14","author":"Sinn","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.aohep.2025.101905_bib0078","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002794","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma","volume":"9","author":"Greten","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.aohep.2025.101905_bib0079","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.2147\/CMAR.S220976","article-title":"Benefits and limitations of a multidisciplinary approach in cancer patient management","volume":"12","author":"Berardi","year":"2020","journal-title":"Cancer Manag Res"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125001309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125001309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T09:35:18Z","timestamp":1764668118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268125001309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1665268125001309"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.101905","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.101905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101905"}}